Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Richard J. Levine, M.D., M.P.H., Chun Lam, M.D., Cong Qian, M.S., Kai F. Yu, Ph.D., Sharon E. Maynard, M.D., Benjamin P. Sachs, M.B., B.S., D.P.H., Baha M. Sibai, M.D., Franklin H. Epstein, M.D., Roberto Romero, M.D., Ravi Thadhani, M.D., M.P.H., S. Ananth Karumanchi, M.D., for the CPEP Study Group
Background Alterations in circulating soluble fms-like tyrosinekinase 1 (sFlt1), an antiangiogenic protein, and placental growthfactor (PlGF), a proangiogenic protein, appear to be involvedin the pathogenesis of preeclampsia. Since soluble endoglin,another antiangiogenic protein, acts together with sFlt1 toinduce a severe preeclampsia-like syndrome in pregnant rats,we examined whether it is associated with preeclampsia in women.
Methods We performed a nested case–control study of healthynulliparous women within the Calcium for Preeclampsia Preventiontrial. The study included all 72 women who had preterm preeclampsia(<37 weeks), as well as 480 randomly selected women —120 women with preeclampsia at term (at 37 weeks), 120 womenwith gestational hypertension, 120 normotensive women who deliveredinfants who were small for gestational age, and 120 normotensivecontrols who delivered infants who were not small for gestationalage.
Results Circulating soluble endoglin levels increased markedlybeginning 2 to 3 months before the onset of preeclampsia. Afterthe onset of clinical disease, the mean serum level in womenwith preterm preeclampsia was 46.4 ng per milliliter, as comparedwith 9.8 ng per milliliter in controls (P<0.001). The meanserum level in women with preeclampsia at term was 31.0 ng permilliliter, as compared with 13.3 ng per milliliter in controls(P<0.001). Beginning at 17 weeks through 20 weeks of gestation,soluble endoglin levels were significantly higher in women inwhom preterm preeclampsia later developed than in controls (10.2ng per milliliter vs. 5.8 ng per milliliter, P<0.001), andat 25 through 28 weeks of gestation, the levels were significantlyhigher in women in whom term preeclampsia developed than incontrols (8.5 ng per milliliter vs. 5.9 ng per milliliter, P<0.001).An increased level of soluble endoglin was usually accompaniedby an increased ratio of sFlt1:PlGF. The risk of preeclampsiawas greatest among women in the highest quartile of the controldistributions for both biomarkers but not for either biomarkeralone.
Conclusions Rising circulating levels of soluble endoglin andratios of sFlt1:PlGF herald the onset of preeclampsia.
Source Information
From the Division of Epidemiology, Statistics, and Prevention Research (R.J.L., K.F.Y.) and the Perinatology Research Branch (R.R.), National Institute of Child Health and Human Development, Department of Health and Human Services, Bethesda, MD; the Center for Vascular Biology, Renal and Molecular and Vascular Medicine Divisions, Departments of Medicine and Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (C.L., B.P.S., F.H.E., S.A.K.); Allied Technology Group, Rockville, MD (C.Q.); the Department of Medicine, George Washington University School of Medicine, Washington, DC (S.E.M.); the Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati (B.M.S.); Wayne State University School of Medicine, Detroit (R.R.); and the Departments of Medicine and Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston (R.T.).
Address reprint requests to Dr. Levine at the NIH/NICHD, Bldg. 6100, Rm. 7B03, Bethesda, MD 20892, or at levinerj{at}mail.nih.gov or to Dr. Karumanchi at Beth Israel Deaconess Medical Center, 330 Brookline Ave., RW 663B, Boston, MA 02215, or at sananth{at}bidmc.harvard.edu.
Guo, Q., Carrero, J. J., Yu, X., Barany, P., Qureshi, A. R., Eriksson, M., Anderstam, B., Chmielewski, M., Heimburger, O., Stenvinkel, P., Lindholm, B., Axelsson, J.
(2009). Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant
0: gfp315v1-gfp315
[Abstract][Full Text]
Chiang, M.-H., Liang, F.-Y., Chen, C.-P., Chang, C.-W., Cheong, M.-L., Wang, L.-J., Liang, C.-Y., Lin, F.-Y., Chou, C.-C., Chen, H.
(2009). Mechanism of Hypoxia-induced GCM1 Degradation: IMPLICATIONS FOR THE PATHOGENESIS OF PREECLAMPSIA. J. Biol. Chem.
284: 17411-17419
[Abstract][Full Text]
Wang, A., Rana, S., Karumanchi, S. A.
(2009). Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis. Physiology
24: 147-158
[Abstract][Full Text]
Levine, R. J., Lindheimer, M. D.
(2009). First-Trimester Prediction of Early Preeclampsia: A Possibility at Last!. Hypertension
53: 747-748
[Full Text]
Feldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E., Ishill, N., Patil, S., Motzer, R. J.
(2009). Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JCO
27: 1432-1439
[Abstract][Full Text]
Singhal, A. B., Kimberly, W. T., Schaefer, P. W., Hedley-Whyte, E. T.
(2009). Case 8-2009 -- A 36-Year-Old Woman with Headache, Hypertension, and Seizure 2 Weeks Post Partum. NEJM
360: 1126-1137
[Full Text]
Hawfield, A., Freedman, B. I.
(2009). Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis
3: 65-73
[Abstract]
Dragun, D., Haase-Fielitz, A.
(2009). Low catechol-O-methyltransferase and 2-methoxyestradiol in preeclampsia: more than a unifying hypothesis. Nephrol Dial Transplant
24: 31-33
[Full Text]
Winn, V. D., Gormley, M., Paquet, A. C., Kjaer-Sorensen, K., Kramer, A., Rumer, K. K., Haimov-Kochman, R., Yeh, R.-F., Overgaard, M. T., Varki, A., Oxvig, C., Fisher, S. J.
(2009). Severe Preeclampsia-Related Changes in Gene Expression at the Maternal-Fetal Interface Include Sialic Acid-Binding Immunoglobulin-Like Lectin-6 and Pappalysin-2. Endocrinology
150: 452-462
[Abstract][Full Text]
Maynard, S. E., Thadhani, R.
(2009). Pregnancy and the Kidney. J. Am. Soc. Nephrol.
20: 14-22
[Abstract][Full Text]
Faye-Petersen, O. M., Crombleholme, T. M.
(2008). Twin-to-Twin Transfusion Syndrome: Part 1. Types and Pathogenesis. NeoReviews
9: e370-e379
[Abstract][Full Text]
Sandrim, V. C., Palei, A. C.T., Metzger, I. F., Gomes, V. A., Cavalli, R. C., Tanus-Santos, J. E.
(2008). Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia. Hypertension
52: 402-407
[Abstract][Full Text]
Leanos-Miranda, A., Marquez-Acosta, J., Cardenas-Mondragon, G. M., Chinolla-Arellano, Z. L., Rivera-Leanos, R., Bermejo-Huerta, S., Romero-Arauz, J. F., Alvarez-Jimenez, G., Ramos-Leon, J. C., Ulloa-Aguirre, A.
(2008). Urinary Prolactin as a Reliable Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Pregnancy Outcomes. J. Clin. Endocrinol. Metab.
93: 2492-2499
[Abstract][Full Text]
Wipff, J., Avouac, J., Borderie, D., Zerkak, D., Lemarechal, H., Kahan, A., Boileau, C., Allanore, Y.
(2008). Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford)
47: 972-975
[Abstract][Full Text]
Munaut, C., Lorquet, S., Pequeux, C., Blacher, S., Berndt, S., Frankenne, F., Foidart, J.-M.
(2008). Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod
23: 1407-1415
[Abstract][Full Text]
Lockwood, C. J., Yen, C.-F., Basar, M., Kayisli, U. A., Martel, M., Buhimschi, I., Buhimschi, C., Huang, S. J., Krikun, G., Schatz, F.
(2008). Preeclampsia-Related Inflammatory Cytokines Regulate Interleukin-6 Expression in Human Decidual Cells. Am. J. Pathol.
172: 1571-1579
[Abstract][Full Text]
Haraldsson, B., Nystrom, J., Deen, W. M.
(2008). Properties of the Glomerular Barrier and Mechanisms of Proteinuria. Physiol. Rev.
88: 451-487
[Abstract][Full Text]
Papageorghiou, A. T., Prefumo, F., Leslie, K., Gaze, D. C., Collinson, P. O., Thilaganathan, B.
(2008). Defective endovascular trophoblast invasion in the first trimester is associated with increased maternal serum ischemia-modified albumin. Hum Reprod
23: 803-806
[Abstract][Full Text]
Karumanchi, S. A., Lindheimer, M. D.
(2008). Preeclampsia Pathogenesis: "Triple A Rating"-Autoantibodies and AntiAngiogenic Factors. Hypertension
51: 991-992
[Full Text]
Huppertz, B.
(2008). Placental Origins of Preeclampsia: Challenging the Current Hypothesis. Hypertension
51: 970-975
[Full Text]
LaMarca, B. D., Gilbert, J., Granger, J. P.
(2008). Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia. Hypertension
51: 982-988
[Full Text]
Maharaj, A. S.R., Walshe, T. E., Saint-Geniez, M., Venkatesha, S., Maldonado, A. E., Himes, N. C., Matharu, K. S., Karumanchi, S. A., D'Amore, P. A.
(2008). VEGF and TGF-{beta} are required for the maintenance of the choroid plexus and ependyma. JEM
205: 491-501
[Abstract][Full Text]
Navankasattusas, S., Whitehead, K. J., Suli, A., Sorensen, L. K., Lim, A. H., Zhao, J., Park, K. W., Wythe, J. D., Thomas, K. R., Chien, C.-B., Li, D. Y.
(2008). The netrin receptor UNC5B promotes angiogenesis in specific vascular beds. Development
135: 659-667
[Abstract][Full Text]
Gilbert, J. S., Ryan, M. J., LaMarca, B. B., Sedeek, M., Murphy, S. R., Granger, J. P.
(2008). Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol.
294: H541-H550
[Abstract][Full Text]
Yinon, Y., Nevo, O., Xu, J., Many, A., Rolfo, A., Todros, T., Post, M., Caniggia, I.
(2008). Severe Intrauterine Growth Restriction Pregnancies Have Increased Placental Endoglin Levels: Hypoxic Regulation via Transforming Growth Factor- 3. Am. J. Pathol.
172: 77-85
[Abstract][Full Text]
Buck Louis, G. M., Hediger, M. L., Pena, J. B.
(2007). Intrauterine exposures and risk of endometriosis. Hum Reprod
22: 3232-3236
[Abstract][Full Text]
Gilbert, J. S., Babcock, S. A., Granger, J. P.
(2007). Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression. Hypertension
50: 1142-1147
[Abstract][Full Text]
Perez-Gomez, E., Villa-Morales, M., Santos, J., Fernandez-Piqueras, J., Gamallo, C., Dotor, J., Bernabeu, C., Quintanilla, M.
(2007). A Role for Endoglin as a Suppressor of Malignancy during Mouse Skin Carcinogenesis. Cancer Res.
67: 10268-10277
[Abstract][Full Text]
Powrie, R. O.
(2007). A 30-Year-Old Woman With Chronic Hypertension Trying to Conceive. JAMA
298: 1548-1558
[Abstract][Full Text]
Troisi, R., Potischman, N., Hoover, R. N.
(2007). Exploring the Underlying Hormonal Mechanisms of Prenatal Risk Factors for Breast Cancer: A Review and Commentary. Cancer Epidemiol. Biomarkers Prev.
16: 1700-1712
[Abstract][Full Text]
Faupel-Badger, J. M., Hsieh, C.-C., Troisi, R., Lagiou, P., Potischman, N.
(2007). Plasma Volume Expansion in Pregnancy: Implications for Biomarkers in Population Studies. Cancer Epidemiol. Biomarkers Prev.
16: 1720-1723
[Abstract][Full Text]
Brinkman-Van der Linden, E. C M, Hurtado-Ziola, N., Hayakawa, T., Wiggleton, L., Benirschke, K., Varki, A., Varki, N.
(2007). Human-specific expression of Siglec-6 in the placenta. Glycobiology
17: 922-931
[Abstract][Full Text]
Masuyama, H., Nakatsukasa, H., Takamoto, N., Hiramatsu, Y.
(2007). Correlation between Soluble Endoglin, Vascular Endothelial Growth Factor Receptor-1, and Adipocytokines in Preeclampsia. J. Clin. Endocrinol. Metab.
92: 2672-2679
[Abstract][Full Text]
Stepan, H., Kramer, T., Faber, R.
(2007). Maternal Plasma Concentrations of Soluble Endoglin in Pregnancies with Intrauterine Growth Restriction. J. Clin. Endocrinol. Metab.
92: 2831-2834
[Abstract][Full Text]
Lindheimer, M. D., Romero, R.
(2007). Emerging Roles of Antiangiogenic and Angiogenic Proteins in Pathogenesis and Prediction of Preeclampsia. Hypertension
50: 35-36
[Full Text]
Rana, S., Karumanchi, S. A., Levine, R. J., Venkatesha, S., Rauh-Hain, J. A., Tamez, H., Thadhani, R.
(2007). Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia. Hypertension
50: 137-142
[Abstract][Full Text]
Hladunewich, M., Karumanchi, S. A., Lafayette, R.
(2007). Pathophysiology of the Clinical Manifestations of Preeclampsia. CJASN
2: 543-549
[Full Text]
Cudmore, M., Ahmad, S., Al-Ani, B., Fujisawa, T., Coxall, H., Chudasama, K., Devey, L. R., Wigmore, S. J., Abbas, A., Hewett, P. W., Ahmed, A.
(2007). Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1. Circulation
115: 1789-1797
[Abstract][Full Text]
Stepan, H., Unversucht, A., Wessel, N., Faber, R.
(2007). Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion. Hypertension
49: 818-824
[Abstract][Full Text]
A correction has been published: N Engl J Med 2006;355(17):1840.
37 weeks), 120 women with gestational hypertension, 120 normotensive women who delivered infants who were small for gestational age, and 120 normotensive controls who delivered infants who were not small for gestational age. 
Previous
